Evidence map›Paper›PMID 40781078›Full record

ArticleCell death & disease2025

Chidamide and cytarabine synergistically treat acute myeloid leukemia: inhibiting ribosome biogenesis via the MYC-RRP9 pathway.

Qing Li, Fangfang Wang, Xinrong Xiang, Lei Zhao, Xuefeng Li, Ying Qu, Jingcao Huang, Yunfan Yang, Yang Dai, Xiao Shuai and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. c-Medical sciences (Basel, Switzerland) · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Qing LiDepartment of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Fangfang WangDepartment of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xinrong XiangDepartment of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Lei ZhaoDepartment of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xuefeng LiDepartment of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Ying QuDepartment of Hematology and Institute of Hematology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jingcao HuangDepartment of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.ORCID http://orcid.org/0000-0002-3041-6440
Yunfan YangDepartment of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yang DaiDepartment of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xiao ShuaiDepartment of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jiazhuo LiuDepartment of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jie HuangDepartment of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yu LiuDepartment of Hematology and Institute of Hematology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.ORCID http://orcid.org/0000-0002-1193-7830
Yu WuDepartment of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. wu_yu@scu.edu.cn.ORCID http://orcid.org/0000-0001-8708-9711

Funding

Department of Science and Technology of Sichuan Province (Sichuan Provincial Department of Science and Technology) 2022YFS0191National Natural Science Foundation of China (National Science Foundation of China) 82370171
6 · The paper itself

Abstract

This study explores innovative therapeutic approaches for acute myeloid leukemia by examining the synergistic effects of the histone deacetylase inhibitor chidamide in combination with cytarabine. In both in vitro and in vivo models, the drug combination demonstrated significant synergism in combating acute myeloid leukemia. Transcriptomic analysis revealed that the combination treatment notably downregulates the MYC signaling pathway. Binding assays, including surface plasmon resonance, molecular docking, and molecular dynamics simulations, further demonstrated that chidamide directly interacts with the C-MYC protein, while cytarabine enhanced this interaction. Delving deeper into the mechanism, we identified RRP9-an essential gene for ribosome biogenesis and a key player in acute myeloid leukemia prognosis-as a critical component of the MYC pathway. It was confirmed that MYC regulates RRP9 expression. Functional assays showed that overexpression of RRP9 promoted acute myeloid leukemia cell proliferation and resistance to the chidamide-cytarabine combination, whereas RRP9 knockdown impaired rRNA synthesis, reduced nucleolar size, and diminished protein production. Ultimately, we found that chidamide combined with cytarabine effectively inhibit ribosome biogenesis in acute myeloid leukemia cells. These results underscore the therapeutic potential of targeting the MYC-RRP9 axis to disrupt ribosome biogenesis in acute myeloid leukemia, offering a promising avenue for acute myeloid leukemia treatment.

Indexed as

AminopyridinesBenzamidesCytarabineLeukemia, Myeloid, AcuteProto-Oncogene Proteins c-mycRibosomesAnimalsCell Line, TumorCell ProliferationDrug SynergismHumansMiceSignal TransductionAminopyridinesBenzamidesCytarabineMYC protein, humanN-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamideProto-Oncogene Proteins c-myc

Identifiers

PMID40781078
PMCPMC12334614

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.